I confess I am disappointed in the choices made by the FDA for its patient-focused drug development program:
http://www.raps.org/focus-online/news/news-article-view/article/3171/section-x-first-class-fda-selects-20-diseases-for-special-regulatory-treatment.aspx
A couple of choices, such as breast and lung cancer, already have plenty of R & D resources, and a couple of others seem like trivial conditions compared to diseases like lupus or amyloidosis.
I know ga_peach worked hard on this issue, and I hope we can be part of the effort in 2016 to have amyloidosis included next time.